Truist Financial Corp Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Truist Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 26, 2022	SELL	$144.95 - $152.29 $3.48 Million - $3.66 Million	-24,002 Reduced 91.8%	2,143 $324,000
Q2 2022 Jul 22, 2022	SELL	$83.14 - $145.99 $6,152 - $10,803	-74 Reduced 0.28%	26,145 $3.81 Million
Q1 2022 Apr 22, 2022	BUY	$110.08 - $142.92 $177,889 - $230,958	1,616 Added 6.57%	26,219 $3.11 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $2.02 Million - $3.01 Million	20,245 Added 464.55%	24,603 $3.39 Million
Q4 2020 Feb 18, 2021	BUY	$65.07 - $98.24 $283,575 - $428,129	4,358 New	4,358 $374,000

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.8B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.